We've detected that Javascript is not enabled. It is required for an optimal survey taking experience.
Please check your browser's settings and make sure Javascript is turned on. Learn how to enable Javascript.

Skip survey header

2011 HCV Council

Page One

1. What are your credentials? *This question is required.

Other credentials

2. How many chronic HCV patients have you seen in your practice in the last 6 months? *This question is required.

3. Of your patients with chronic HCV, what percentage have failed to achieve an SVR on pharmacologic therapy? *This question is required.

Grade your level of support for the following statements using the scale below:

1 - Accept completely
2 - Accept with some reservations
3 - Accept with major reservations
4 - Reject with reservations
5 - Reject completely

4. Statement 1: IL28B genotyping should be performed in all candidates for PI/PEG-IFN/RBV therapy.

5. Statement 2: PI/PEG-IFN/RBV is the standard of care in all HCV genotype 1 treatment-naïve patients.

6. Statement 3: PI/PEG-IFN/RBV is the standard of care in all HCV genotype 1 treatment-experienced patients.

7. Statement 4: Response-guided therapy should be utilized in all treatment-naïve patients treated with PI/PEG-IFN/RBV regimens.

8. Statement 5: Response-guided therapy should be utilized in all treatment-experienced patients treated with PI/PEG-IFN/RBV regimens.

9. Statement 6: Null responders to previous PEG-IFN/RBV with minimal liver disease should not be treated with PI-based therapy.

10. Statement 7: Viral resistance testing has no clinical utility in the management of HCV patients receiving PI/PEG-IFN/RBV therapy.

11. Statement 8: Response to lead-in therapy should not influence the decision to initiate a PI-based regimen.

12. Statement 9: Patients treated with a telaprevir-based regimen who develop a severe rash should be switched to a boceprevir-based regimen.

13. Statement 10: In PI-based HCV treatment regimens, erythropoietin should be used to manage anemia prior to RBV dose reduction.

14. Statement 11: PI/PEG-IFN/RBV combinations are first line therapy in patients with HCV–HIV co-infection.

15. Statement 12: PI/PEG-IFN/RBV combinations are first line therapy in patients with HCV–transplant populations.

16. Are you interested in receiving the findings of the expert panel meeting from the HCV Council 2011; the outcomes of this field evaluation; and information on similar topics? *This question is required.

Please provide your email address. *This question is required.

Survey Software powered by SurveyGizmo